A RANDOMIZED, CONTROLLED, OPEN-LABEL, SINGLE-CENTER, PARALLEL GROUP STUDY TO ASSESS THE EFFECT OF MIRCERA ON DELAYING DIALYSIS IN ANEMIC PATIENTS WITH STAGE 5 CHRONIC KIDNEY DISEASE NOT ON DIALYSIS

Start Date19 Mar 2019

Sponsor / Collaborator-

NCT03552393 / CompletedPhase 2

An Open-Label, Single-Arm, Multicenter Study to Ascertain the Optimal Starting Dose of MIRCERA® Given Subcutaneously for the Maintenance Treatment of Anemia in Pediatric Patients With Chronic Kidney Disease on Dialysis or Not Yet on Dialysis.

Ascertain the starting dose of Mircera given subcutaneously for the maintenance treatment of anemia in pediatric participants with chronic kidney disease (CKD) on dialysis or not yet on dialysis when switching from stable subcutaneous (SC) maintenance treatment with epoetin alfa, epoetin beta, or darbepoetin alfa.

Start Date03 Aug 2018

Sponsor / Collaborator

Hoffmann-La Roche, Inc.

NCT03427801 / CompletedNot ApplicableIIT

Effect of Erythropoiesis-Stimulating Agent Therapy in Patients Receiving Palliative Care of Chronic Kidney Disease

An observational study to evaluate the effect of erythropoiesis-stimulating agents in treating anaemia of renal disease among adult patients receive palliative care instead of dialysis.

Start Date01 Mar 2017

Sponsor / Collaborator

The Chinese University of Hong Kong

100 Clinical Results associated with Methoxy Polyethylene Glycol-Epoetin Beta

100 Translational Medicine associated with Methoxy Polyethylene Glycol-Epoetin Beta

100 Patents (Medical) associated with Methoxy Polyethylene Glycol-Epoetin Beta

245

Literatures (Medical) associated with Methoxy Polyethylene Glycol-Epoetin Beta

22 Sep 2024·Drug Testing and Analysis

Discovery of Biomarkers of a Recombinant Human Erythropoietin Administration to Thoroughbred Geldings by Label-Free Proteomics.

Article

Author: Wong, Kin-Sing ; Farrington, Adrian F ; Bond, Amanda J ; Cheung, Hiu Wing ; Ho, Emmie N M ; Tam, Jimmy C L ; Wan, Terence S M

Erythropoiesis-stimulating agents (ESAs) continue to be a significant threat to the integrity of human and equine sports. Besides conventional direct testing, monitoring the biomarkers associated with the effects of ESAs may provide a complementary approach via indirect detection to enhance doping control. In this study, we applied label-free proteomics to discover plasma protein biomarkers in Thoroughbred geldings after administration with a long-acting form of recombinant human erythropoietin (rhEPO), methoxy polyethylene glycol epoetin beta, Mircera. Increased haematocrit, haemoglobin and red blood cell (RBC) levels were evidenced as early as 4 days post-administration in all three horses to varying extents. Tryptic peptides were obtained from plasma samples and analysed by nanoflow ultra-high-performance liquid chromatography-high-resolution tandem mass spectrometry (nano-UHPLC-HRMSMS) using data-independent acquisition. Differential protein abundance analysis has shortlisted seven protein biomarker candidates that showed significant changes specifically after Mircera administration in the treated but not in the control geldings, which comprised downregulation of two proteins, haptoglobin (HP) and haemopexin (HPX), and upregulation of five proteins, transferrin receptor 1 (TFR1), phospholipid transfer protein (PLTP), tenascin C (TNC), vascular cell adhesion molecule 1 (VCAM1) and galectin 3 binding protein (LGALS3BP). Multivariate analysis of plasma proteome has allowed the classification of control and treated samples. This is the first report on the discovery of plasma protein biomarkers of rhEPO administration to geldings. The results lay a foundation for applications of protein biomarkers for controlling the misuse of ESAs.

31 May 2024·Kidney research and clinical practice

Efficacy and cost-effectiveness of darbepoetin alfa once every 4 weeks versus continuous erythropoietin receptor activator once every 4 weeks for anemia correction in patients with chronic kidney disease not on dialysis

Article

Author: Choi, Soo Jeong ; Yu, Byung Chul ; Park, Moo Yong ; Kim, Jin Kuk ; Lee, Kyung Ho ; Park, Geo Neul ; Moon, Ji Eun

Background: For anemia management in patients with chronic kidney disease not on dialysis, darbepoetin alfa (DA), which has a shorter half-life but is more inexpensive than continuous erythropoietin receptor activator (CERA), is preferred in Korea. This study evaluated the efficacy, safety, and cost-effectiveness of once-in-4-weeks DA compared with once-in-4-weeks CERA in patients with chronic kidney disease not on dialysis. Methods: In this randomized, prospective, non-inferiority study, 40 erythropoiesis-stimulating agent–naïve patients with chronic kidney disease not on dialysis were randomized 1:1 to the DA group and CERA group. They received the study drug once in 4 weeks during 10- or 12-week correction period and 24-week efficacy evaluation period. The primary outcomes were the mean difference in the changes in hemoglobin levels between baseline and efficacy evaluation period and hemoglobin response rates during the correction period. The secondary outcomes included differences in adverse events and costs. Results: DA was non-inferior to CERA for anemia correction; the mean difference in the change in hemoglobin levels between the groups was –0.070 g/dL (95% confidence interval, –0.730 to 0.590 g/dL). Hemoglobin response rates were 100% with DA and 94.1% with CERA. Adverse events were comparable. The mean cost of DA was approximately one-third that of CERA (34,100 ± 7,600 Korean won/4 weeks vs. 115,500 ± 23,600 Korean won/4 weeks; p < 0.001). Conclusion: Once-in-4-weeks DA safely corrects anemia in erythropoiesis-stimulating agent–naïve patients with chronic kidney disease not on dialysis and is more cost-effective than once-in-4-weeks CERA.

01 Mar 2024·Pediatric nephrology (Berlin, Germany)

Real-world evidence on the dosing and safety of C.E.R.A. in pediatric dialysis patients: findings from the International Pediatric Dialysis Network registries

Article

Author: Warady, Bradley A ; Rutten-Jacobs, Loes ; Schmitt, Claus Peter ; Coccia, Paula A ; Yap, Hui-Kim ; Reigner, Sylvie Meyer ; Sander, Anja ; Studer, Milena ; Schaefer, Franz ; Kohlhas, Laura ; Cano, Francisco ; Vondrak, Karel

Abstract:

Background:

This retrospective real-world study used data from two registries, International Pediatric Peritoneal Dialysis Network (IPPN) and International Pediatric Hemodialysis Network (IPHN), to characterize the efficacy and safety of continuous erythropoietin receptor activator (C.E.R.A.) in pediatric patients with chronic kidney disease (CKD) on peritoneal dialysis (PD) or hemodialysis (HD).

Methods:

IPPN and IPHN collect prospective data (baseline and every 6 months) from pediatric PD and HD centers worldwide. Demographics, clinical characteristics, dialysis information, treatment, laboratory parameters, number and causes of hospitalization events, and deaths were extracted for patients on C.E.R.A. treatment (IPPN: 2007–2021; IPHN: 2013–2021).

Results:

We analyzed 177 patients on PD (median age 10.6 years) and 52 patients on HD (median age 14.1 years) who had ≥ 1 observation while being treated with C.E.R.A. The median (interquartile range [IQR]) observation time under C.E.R.A. exposure was 6 (0–12.5) and 12 (0–18) months, respectively. Hemoglobin concentrations were stable over time; respective means (standard deviation) at last observation were 10.9 (1.7) g/dL and 10.4 (1.7) g/dL. Respective median (IQR) monthly C.E.R.A. doses at last observation were 3.5 (2.3–5.1) µg/kg, or 95 (62–145) µg/m2 and 2.1 (1.2–3.4) µg/kg, or 63 (40–98) µg/m2. Non-elective hospitalizations occurred in 102 (58%) PD and 32 (62%) HD patients. Seven deaths occurred (19.8 deaths per 1000 observation years).

Conclusions:

C.E.R.A. was associated with efficient maintenance of hemoglobin concentrations in pediatric patients with CKD on dialysis, and appeared to have a favorable safety profile. The current analysis revealed no safety signals.

Graphical abstract:

News (Medical) associated with Methoxy Polyethylene Glycol-Epoetin Beta

24 Oct 2024

·www.prnewswire.com

Fresenius Medical Care Recent Study Validates Innovative Anemia Therapy Software Improves Clinical Outcomes for Hemodialysis Patients

This randomized controlled study demonstrates that patients achieved a higher percentage of target hemoglobin levels Patients receiving anemia management assistance via the software tools saw a 25% reduction in erythropoiesis-stimulating agent (ESA) usage The software's physiology-based model and predictive controller were associated with improved hemoglobin fluctuations and variability, offering a higher likelihood of more stable hemoglobin levels compared to standard care protocols BAD HOMBURG, Germany, Oct. 24, 2024 /PRNewswire/ -- Fresenius Medical Care (FME), the world's leading provider of products and services for individuals with renal diseases, today announced innovative results from a multicenter, randomized controlled trial in the United States that highlights the potential benefits of personalized anemia therapy for patients undergoing hemodialysis. The study, "Effects of Individualized Anemia Therapy on Hemoglobin Stability," published in the Clinical Journal of the American Society of Nephrology (CJASN), demonstrates that the use the anemia therapy assistance software, attained improved hemoglobin stability and reduced the use of erythropoiesis-stimulating agents (ESAs) among hemodialysis patients participating in the study1. This innovative approach, which is part of the company's ongoing commitment to improve patient outcomes, is powered by a physiology-driven mathematical model designed to deliver personalized treatment recommendations. The results showed a 25% improvement in hemoglobin target attainment for patients receiving individualized therapy compared to standard care. The findings are significant because maintaining target hemoglobin levels with less variability in patients can help reduce the risk of developing cardiovascular problems. "This study exemplifies how data-driven insights can lead to more personalized treatments," said Dr. Frank Maddux, MD, Chief Global Medical Officer of Fresenius Medical Care. "By integrating cutting-edge computational techniques, we are paving the way for more precise, patient-centered care, which not only improves clinical outcomes but also enhances quality of life for people on dialysis. Our commitment is to continue developing innovative solutions that transform kidney care worldwide." The study, conducted by Dr. Doris H. Fuertinger and colleagues, enrolled 96 patients from five Fresenius Kidney Care clinics across the United States. Patients were randomized into two groups: one receiving personalized anemia treatment recommendations from the software, and the other following standard protocols. Over a 26-week period, patients in the personalized therapy group achieved greater hemoglobin stability, experienced fewer fluctuations, and required significantly less ESA, reducing their dose on average by 25%. Additional key findings suggest hemoglobin variability was significantly lower in the personalized therapy group, contributing to more stable patient outcomes. "This prospective, randomized controlled study highlights the value of physiological models and computer-aided individualization of therapy to improve clinical outcomes for people on dialysis," said Dr. Fuertinger, Head of Computational Medicine, Fresenius Medical Care. "By harnessing the power of these technologies, we are able to provide clinicians with actionable insights that may enable more precise and efficient therapy management." The study underscores FME's vision of transforming renal care by designing cloud-based technologies and predictive analytics that can potentially integrate into daily clinical practice. As healthcare moves toward greater personalization, the company is committed to utilizing these advanced tools to optimize patient care and support clinicians in making data-driven decisions. "We are proud to be at the forefront of this important research by developing novel approaches to treat end-stage renal failure," said Dr. Katarzyna Mazur-Hofsaess, member of the Management Board of Fresenius Medical Care and responsible for the segment Care Enablement. "Our commitment to new technology continues to support the individualization of care for people living with kidney disease." For more information on Fresenius Medical Care's innovations and research in renal care, visit . About Fresenius Medical Care: Fresenius Medical Care is the world's leading provider of products and services for individuals with renal diseases of which around 4.1 million patients worldwide regularly undergo dialysis treatment. Through its network of 3,757 dialysis clinics, Fresenius Medical Care provides dialysis treatments for approx. 311,000 patients around the globe. Fresenius Medical Care is also the leading provider of dialysis products such as dialysis machines or dialyzers. Fresenius Medical Care is listed on the Frankfurt Stock Exchange (FME) and on the New York Stock Exchange (FMS). For more information visit the Company's website at . Disclaimer: This release contains forward-looking statements that are subject to various risks and uncertainties. Actual results could differ materially from those described in these forward-looking statements due to various factors, including, but not limited to, changes in business, economic and competitive conditions, legal changes, regulatory approvals, impacts related to the COVID-19 pandemic results of clinical studies, foreign exchange rate fluctuations, uncertainties in litigation or investigative proceedings, and the availability of financing. These and other risks and uncertainties are detailed in Fresenius Medical Care's reports filed with the U.S. Securities and Exchange Commission. Fresenius Medical Care does not undertake any responsibility to update the forward-looking statements in this release. 1 Fuertinger, Doris H., et al. "Effects of Individualized Anemia Therapy on Clinical Outcomes in Patients Undergoing Hemodialysis." Clinical Journal of the American Society of Nephrology, vol. 19, no. 9, 2024, pp. 1100-1110. Media contact Kirsten Stratton T +1 781 929 8096 [email protected] Christine Peters T +49 160 60 66 770 [email protected] Contact for analysts and investors Dr. Dominik Heger T +49 6172 609 2601 [email protected] SOURCE Fresenius Medical Care Holdings, Inc. WANT YOUR COMPANY'S NEWS FEATURED ON PRNEWSWIRE.COM? 440k+ Newsrooms & Influencers 9k+ Digital Media Outlets 270k+ Journalists Opted In GET STARTED

Clinical Result

03 Apr 2024

·www.pharmaceutical-technology.com

EC approves Bristol Myers Squibb’s Reblozyl for first-line MDS treatment

The approval for Bristol Myers Squibb’s Reblozyl is applicable in all the EU member states. Katherine Welles / Shutterstock.com. The European Commission (EC) has granted expanded approval for Bristol Myers Squibb ‘s (BMS) Reblozyl (luspatercept) as a first-line treatment for adults with transfusion-dependent anaemia associated with very low, low and intermediate-risk myelodysplastic syndromes (MDS). The decision is applicable in all the member states of the European Union (EU). The EC’s expanded approval is based on the results from the open-label, randomised Phase III COMMANDS study. The trial assessed the efficacy and safety of Reblozyl compared to epoetin alfa, an erythropoiesis-stimulating agent, in treating anaemia due to MDS. It included subjects who needed red blood cell (RBC) transfusions and had not previously received erythropoiesis-stimulating agents. See Also: Alexion’s Voydeya gains FDA approval for extravascular haemolysis Novartis gets grant for treatment of cocaine use disorder using mavoglurant Reblozyl significantly outperformed epoetin alfa in achieving concurrent RBC transfusion independence and a rise in haemoglobin levels – the study’s primary endpoint. Safety results were in line with previous studies on MDS, with no significant differences in progression to acute myeloid leukaemia or total deaths between the study arms. This approval is the fourth indication authorised for Reblozyl in Europe, positioning it as a first-in-class treatment for people with disease-related anaemia and the first therapy to demonstrate superior efficacy versus epoetin alfa in lower-risk MDS (LR-MDS). Reblozyl is a product of a global collaboration and is co-promoted in North America by Merck (MSD), following its acquisition of Acceleron Pharma in November 2021. It has also been approved in the US and Japan for the first-line treatment of anaemia associated with LR-MDS. Bristol Myers Squibb European Markets senior vice-president and head Monica Shaw stated: “With this approval for Reblozyl as a first-line treatment for anaemia in adults with LR MDS, more patients in the EU will have the potential to become transfusion independent for longer periods compared to current options available. “This milestone underscores our ongoing commitment to developing new options for patients with disease-related anaemia.” Last month, the EC approved BMS’ Abecma (idecabtagene vicleucel; ide-cel) to treat adults with relapsed and refractory multiple myeloma .

Drug ApprovalPhase 3Clinical Result

13 Feb 2024

·www.businesswire.com

Injectable Hematology Growth Factors Report 2024 - Evolution in Therapeutic Care - ResearchAndMarkets.com

DUBLIN--( BUSINESS WIRE )--The "Injectable Hematology Growth Factors Report" has been added to ResearchAndMarkets.com's offering. This report is a comprehensive evaluation and analysis of the technology, products, and participants providing the driving force behind this evolving segment of the healthcare sector. The study is designed to provide drug company decision-makers, drug delivery developers, device designers, healthcare marketers, and supply chain participants with a detailed understanding of the economics, technologies, and opportunities for injection devices designed for patient self-administration. Provider organization business managers, healthcare administrators, and investors will also benefit from this study. Evolution in Therapeutic Care Several recombinant hematologic growth factors or agonists for their receptors have been produced that are useful in treating anemia, neutropenia, and thrombocytopenia, particularly in patients with end-stage renal disease or aplastic anemia or who have received cancer chemotherapy or a hematopoietic cell transplant. The shift in as-supplied packaging from single and multi-use vials to prefilled injection devices will accelerate over the next five years as drug developers move to empower an increasing number of chronically ill patients. The powerful physiological effects of antibodies, hormones, and other biological drugs also increase the need for safety and compliance. What You Will Learn Provides detailed analysis of injectable hematology growth factors delivery and device strategies, and product development factors. Assesses key markets, market dynamics, and market demographics. Analyzes therapeutic demand drivers and evaluates injectable drug products in a number of key therapeutic segments. Provides market data and forecasts. Profiles market sector participants, their product development activities, business strategies, and corporate alliances and affiliations Assesses the importance of alliances and partnerships on drug product commercialization. Evaluates the impact of economic, technology, and regulatory factors Key Topics Covered: Hematology Market Dynamics Competitive Factors Proliferation of Biological Drugs Product Manufacturers Hematology Growth Factors Devices for Administering Injectable Growth Factors Device Selection - Stability and Material Issues Competitive Landscape Prefilled Syringes Pen Injectors Dual Chamber Pens Emerging Devices Injectable Hematology Growth Factors - Product Assessment Abseamed Accofil Aranesp Binocrit Biograstim Biopoin Epoetin Alfa Hexal Eporatio Filgrastim Hexal Fulphila Granix Grastofil Mircera NeoRecormon Neulasta Neupogen Nivestim Ratiograstim Retacrit Rolvedon Silapo Tevagrastim Udenyca (Coherus BioSciences) Zarzio Ziextenzo Market Assessment Anemia Hematopoietic Stem Cell Transplant Advanced Kidney Disease Neutropenia Predonation of Autologous Blood Company Profiles Companies Mentioned AbZ-Pharma Accord Healthcare Amgen Genentech Hexal AG Medice Arzneimittel Mylan International Novartis Pfizer Ratiopharm Rentscler Biotechnologie Roche Sandoz Stada Arzneimittel AG Teva Pharmaceuticals For more information about this report visit https://www.researchandmarkets.com/r/bktosb About ResearchAndMarkets.com ResearchAndMarkets.com is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.

ASH

100 Deals associated with Methoxy Polyethylene Glycol-Epoetin Beta

External Link

KEGG	Wiki	ATC	Drug Bank
-	Methoxy Polyethylene Glycol-Epoetin Beta	B03XA03	DB09107

R&D Status

Approved

10 top approved records.

to view more data

Indication	Country/Location	Organization	Date
Anemia	CN	Roche Pharma (Schweiz) AG	28 Apr 2018
Anemia of renal disease	JP	Chugai Pharmaceutical Co., Ltd.	22 Apr 2011
chronic renal failure anemia	EU	Roche Registration GmbH	20 Jul 2007
chronic renal failure anemia	IS	Roche Registration GmbH	20 Jul 2007
chronic renal failure anemia	LI	Roche Registration GmbH	20 Jul 2007
chronic renal failure anemia	NO	Roche Registration GmbH	20 Jul 2007

Developing

10 top R&D records.

to view more data

Indication	Highest Phase	Country/Location	Organization	Date
Peritoneal dialysis complication	Phase 3	JP	Chugai Pharmaceutical Co., Ltd.	01 Feb 2007
Nephrosis	Phase 3	JP	Chugai Pharmaceutical Co., Ltd.	01 Jan 2007
Chronic Kidney Diseases	Phase 3	US	Hoffmann-La Roche, Inc.	01 Feb 2004
Chronic Kidney Diseases	Phase 3	BR	Hoffmann-La Roche, Inc.	01 Feb 2004
Chronic Kidney Diseases	Phase 3	CA	Hoffmann-La Roche, Inc.	01 Feb 2004
Chronic Kidney Diseases	Phase 3	CZ	Hoffmann-La Roche, Inc.	01 Feb 2004
Chronic Kidney Diseases	Phase 3	FR	Hoffmann-La Roche, Inc.	01 Feb 2004
Chronic Kidney Diseases	Phase 3	DE	Hoffmann-La Roche, Inc.	01 Feb 2004
Chronic Kidney Diseases	Phase 3	GR	Hoffmann-La Roche, Inc.	01 Feb 2004
Chronic Kidney Diseases	Phase 3	IT	Hoffmann-La Roche, Inc.	01 Feb 2004

Clinical Result

Indication

Phase

Evaluation

View All Results

Study	Phase	Population	Analyzed Enrollment	Group	Results	Evaluation	Publication Date


ISN WCN2023	Not Applicable	Chronic Kidney Diseases hemoglobin \| eGFR	225	CERA	zgeijxyibf(gvamamlqnp) = mrwblqnwst sljmfyvpqr (teedktqvul, 1.05) View more	Positive	01 Mar 2023
CROWNWeb (ASN2022)	Not Applicable	Maintenance erythropoietin resistance index (ERI) \| hemoglobin (Hb) \| transferrin saturation (TSAT)	-	Epoetin alfa (EPO)	zzfploxcjg(btehhueppw) = ujjjbghqhv mzfpbqqdxz (bjjsfvdlkj ) View more	-	03 Nov 2022
				Darbepoetin alfa (DPO)	zzfploxcjg(btehhueppw) = nxipsaubkv mzfpbqqdxz (bjjsfvdlkj ) View more
NCT03552393 (SKIPPER, ERA2022)	Phase 2	Anemia in chronic kidney disease Maintenance	-	C.E.R.A. SC every 4 weeks	abthlqfcrl(mcuqjsqbjt) = abtetotosm opsnaaexts (eyxqgultpr, 1.03) View more	Positive	03 May 2022
NCT03552393 (SKIPPER, CTgov)	Phase 2	Anemia \| Chronic Kidney Diseases	40	Mircera	epviiqmglj(dsmduvpcyv) = rgemqxsbto winvedmfjq (ziwuocalbq, zofsoynajp - jnouxnrpuc) View more	-	07 Mar 2022
ASN2021	Not Applicable	-	260	IV PEG-epoetin beta	yxjexcksnu(snskrnqmqg) = kwcpkqooay vsbauiloow (zgnxbeoycy ) View more	Positive	27 Oct 2021
				sc epoetin beta	yxjexcksnu(snskrnqmqg) = ezdtnbmdbv vsbauiloow (zgnxbeoycy ) View more
OptumLabs Data Warehouse (ASN2020)	Not Applicable	Anemia hemoglobin \| eGFR \| diabetes ... View more	-	Erythropoiesis-Stimulating Agent	nxrvxiafwf(fdviphetqb) = btknrqufzp nkzqqmglba (vkusvssusc )	Positive	19 Oct 2020
				Erythropoiesis-Stimulating Agent	nxrvxiafwf(fdviphetqb) = nwityshwwr nkzqqmglba (vkusvssusc )
PARAMOUNT-HD (ERA2020)	Not Applicable	Maintenance	4,034	CERA	cagvcudkck(nnijoundio) = rrvmxyehnh hkgmnbfbol (sffvuetofw )	Positive	06 Jun 2020
NCT00773513 (Pubmed \| Clin J Am Soc Nephrol)	Phase 4	Anemia in chronic kidney disease	2,818	Methoxy Polyethylene Glycol-Epoetin Beta	rhpozcppvh(ttgjllhfpl): HR = 1.06 (95% CI, 0.94 - 1.19) View more	-	06 Dec 2019
				Reference Erythropoiesis-Stimulating Agents
PARAMOUNT-HD (ASN2019)	Not Applicable	Maintenance hemoglobin	304	Epoetin Beta Pegol	ezsbufkowj(vomsgsazew) = kguojitkci vtsbsikamv (dqmdysakvu ) View more	Positive	05 Nov 2019
				Epoetin Beta Pegol	ezsbufkowj(vomsgsazew) = bussakiuse vtsbsikamv (dqmdysakvu ) View more
ASN2019	Not Applicable	EPCs \| vascular endothelial growth factor \| matrix metalloproteinase-2 (MMP-2) ... View more	42	Recombinant human erythropoietin (rhEPO)	hwoidgflyx(susdtfmaki) = gdldvtmwnl tlxldmllew (uefijpoqzo )	-	05 Nov 2019
				Darbepoetin (DA)	hwoidgflyx(susdtfmaki) = altckimlhr tlxldmllew (uefijpoqzo )

Translational Medicine

Boost your research with our translational medicine data.

view full example data

Deal

Boost your decision using our deal data.

view full example data

Core Patent

Boost your research with our Core Patent data.

view full example data

Clinical Trial

Identify the latest clinical trials across global registries.

view full example data

Approval

Accelerate your research with the latest regulatory approval information.

view full example data

Regulation

Understand key drug designations in just a few clicks with Synapse.

view full example data

Chat with Hiro

Get started for free today!

Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.

Start your data trial now!

Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.

Bio

Bio Sequences Search & Analysis

Chemical

Chemical Structures Search & Analysis